It's undeniable how drastically clinical trials have evolved in the almost four years since the pandemic transformed the landscape of clinical research. Today, the digital and decentralized tools and technologies that enabled clinical trials to continue during the COVID-19 pandemic have become integral components of nearly all clinical trials, a significant departure from the dynamics of 2019.
Both the FDA and EMA have embraced capabilities that were originally categorized as "DCT (Decentralized clinical trials)." Earlier this year, these regulatory bodies issued long-awaited guidelines regarding decentralized clinical trials and their associated technologies.
As a result, cutting-edge clinical research technologies such as eConsent, eCOA, and telehealth are on the cusp of experiencing remarkable growth. Read the article below to learn how your teams can continue to advance in a pragmatic way.